 Opiant Pharmaceuticals Inc NASDAQ: OPNT announced topline results from a pharmacodynamic PD study for OPNT003, nasal nalmefene for opioid overdose. This crossover study conducted in healthy volunteers compared 3 mg nasal nalmefene hydrochloride with 4 mg nasal naloxone. 